Santé publique France, French national public health agency, Saint-Maurice, France.
Euro Surveill. 2020 Jan;25(4). doi: 10.2807/1560-7917.ES.2020.25.4.1900191.
BackgroundSurveillance of tuberculosis (TB) treatment outcome, for which reporting has been mandatory in France since 2007, is a key component of TB control.AimWe aimed to present surveillance data for non-multidrug-resistant (MDR) cases reported between 2008 and 2014, and identify factors associated with potentially unfavourable treatment outcome.MethodsPatients were classified according to their treatment outcome 12 months after beginning treatment. Poisson regression with a robust error variance was used to investigate factors associated with potentially unfavourable treatment outcome. Missing data were handled using multiple imputation.ResultsA total of 22,526 cases were analysed for treatment outcome. Information available on treatment outcome increased between 2008 (60%) and 2014 (71%) (p < 0.001). During this period, 74.1% of cases completed treatment, increasing from 73.0% in 2008 to 76.9% in 2014 (p < 0.001). This proportion was 74.0% in culture-positive pulmonary cases. Overall, 19.8% of cases had a potentially unfavourable outcome, including lost-to-follow-up, transferred out, still on treatment, death related to TB and interrupted treatment. Potentially unfavourable outcome was significantly associated with TB severity, residing in congregate settings, homelessness, being a smear-positive pulmonary case, being born abroad and residing in France for < 2 years, history of previous anti-TB treatment and age > 85 years.ConclusionMonitoring of treatment outcome is improving over time. The increase in treatment completion over time suggests improved case management. However, treatment outcome monitoring needs to be strengthened in cases belonging to population groups where the percentage of unfavourable outcome is the highest and in cases where surveillance data shows poorer documented follow-up.
背景
自 2007 年以来,法国一直要求报告结核病(TB)治疗结果,这是结核病控制的关键组成部分。
目的
我们旨在介绍 2008 年至 2014 年期间报告的非耐多药(MDR)病例的监测数据,并确定与潜在不良治疗结果相关的因素。
方法
根据治疗开始后 12 个月的治疗结果对患者进行分类。使用具有稳健误差方差的泊松回归来研究与潜在不良治疗结果相关的因素。使用多重插补处理缺失数据。
结果
对 22526 例治疗结果进行了分析。2008 年(60%)和 2014 年(71%)之间可获得的治疗结果信息增加(p < 0.001)。在此期间,74.1%的病例完成了治疗,从 2008 年的 73.0%增加到 2014 年的 76.9%(p < 0.001)。培养阳性肺部病例的这一比例为 74.0%。总体而言,19.8%的病例治疗结果不理想,包括失访、转出、仍在治疗、与结核病相关的死亡和治疗中断。潜在不良结局与结核病严重程度、居住在集体环境中、无家可归、痰涂片阳性肺部病例、在国外出生且在法国居住时间<2 年、有既往抗结核治疗史和年龄>85 岁显著相关。
结论
随着时间的推移,治疗结果监测得到了改善。随着时间的推移,治疗完成率的提高表明病例管理得到了改善。然而,需要加强在不良结局比例最高的人群和监测数据显示随访记录较差的人群中进行治疗结果监测。